{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T00:16:42Z","timestamp":1783469802142,"version":"3.55.0"},"reference-count":33,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,4,26]],"date-time":"2022-04-26T00:00:00Z","timestamp":1650931200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.clml.2022.04.016","type":"journal-article","created":{"date-parts":[[2022,4,22]],"date-time":"2022-04-22T02:46:35Z","timestamp":1650595595000},"page":"670-679","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Impact of Hypomethylating Agent Use on Hospital and Emergency Room Visits, and Predictors of Early Discontinuation in Patients With Higher-Risk Myelodysplastic Syndromes"],"prefix":"10.1016","volume":"22","author":[{"given":"Amer M.","family":"Zeidan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Namita","family":"Joshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hrishikesh","family":"Kale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Jhih","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shelby","family":"Corman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tehseen","family":"Salimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5031-302X","authenticated-orcid":false,"given":"Robert S.","family":"Epstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2022.04.016_bib0001","doi-asserted-by":"crossref","DOI":"10.1177\/2040620720955006","article-title":"Emerging treatment options for patients with high-risk myelodysplastic syndrome","volume":"11","author":"Bewersdorf","year":"2020","journal-title":"Ther Adv Hematol"},{"key":"10.1016\/j.clml.2022.04.016_bib0002","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.annonc.2020.11.002","article-title":"Myelodysplastic syndromes: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up(dagger)","volume":"32","author":"Fenaux","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2022.04.016_bib0003","unstructured":"Surveillance, Epidemiology, and End Results Program. SEER*Explorer. Myelodysplastic syndromes (MDS). 2021. Available at: https:\/\/seer.cancer.gov\/explorer\/index.html. Accessed 10 June 2021."},{"key":"10.1016\/j.clml.2022.04.016_bib0004","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.blre.2018.09.001","article-title":"Epidemiology of myelodysplastic syndromes: why characterizing the beast is a prerequisite to taming it","volume":"34","author":"Zeidan","year":"2019","journal-title":"Blood Rev"},{"key":"10.1016\/j.clml.2022.04.016_bib0005","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1182\/blood.V89.6.2079","article-title":"International scoring system for evaluating prognosis in myelodysplastic syndromes","volume":"89","author":"Greenberg","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.04.016_bib0006","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1182\/blood-2012-03-420489","article-title":"Revised international prognostic scoring system for myelodysplastic syndromes","volume":"120","author":"Greenberg","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.04.016_bib0007","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.3324\/haematol.2011.044602","article-title":"Impact of the degree of anemia on the outcome of patients with myelodysplastic syndrome and its integration into the WHO classification-based Prognostic Scoring System (WPSS)","volume":"96","author":"Malcovati","year":"2011","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2022.04.016_bib0008","doi-asserted-by":"crossref","first-page":"3503","DOI":"10.1200\/JCO.2006.08.5696","article-title":"Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes","volume":"25","author":"Malcovati","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2022.04.016_bib0009","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1182\/blood-2018-10-844696","article-title":"Treatment of MDS","volume":"133","author":"Platzbecker","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.04.016_bib0010","unstructured":"National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae): Myelodysplastic Syndromes Version 3.2021. Available at: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/mds.pdf. Accessed 1 October 2021."},{"key":"10.1016\/j.clml.2022.04.016_bib0011","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1002\/ajh.24930","article-title":"Myelodysplastic syndromes: 2018 update on diagnosis, risk-stratification and management","volume":"93","author":"Montalban-Bravo","year":"2018","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2022.04.016_bib0012","unstructured":"Celgene Corporation. Azacitidine (Vidaza) Prescribing Information. March 2020. Available at: https:\/\/packageinserts.bms.com\/pi\/pi_vidaza.pdf. Accessed 1 October 2021."},{"key":"10.1016\/j.clml.2022.04.016_bib0013","unstructured":"Otsuka. Decitabine (Dacogen). December 2018. Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/021790s021lbl.pdf. Accessed 1 November 2021."},{"key":"10.1016\/j.clml.2022.04.016_bib0014","series-title":"INQOVI\u00ae (decitabine and cedazuridine) tablets, for oral use. US highlights of prescribing information","year":"2020"},{"key":"10.1016\/j.clml.2022.04.016_bib0015","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1200\/JCO.2002.04.117","article-title":"Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B","volume":"20","author":"Silverman","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2022.04.016_bib0016","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1002\/cncr.21792","article-title":"Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study","volume":"106","author":"Kantarjian","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2022.04.016_bib0017","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S1470-2045(09)70003-8","article-title":"Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study","volume":"10","author":"Fenaux","year":"2009","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2022.04.016_bib0018","doi-asserted-by":"crossref","first-page":"e206","DOI":"10.1016\/j.clml.2020.10.013","article-title":"Under-use of hypomethylating agents in patients with higher-risk myelodysplastic syndrome in the United States: a large population-based analysis","volume":"21","author":"Corman","year":"2021","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"Suppl 1","key":"10.1016\/j.clml.2022.04.016_bib0019","doi-asserted-by":"crossref","first-page":"3495","DOI":"10.1182\/blood-2019-124878","article-title":"Treatment patterns and outcomes in patients with myelodysplastic syndromes treated with hypomethylating agents: a SEER-Medicare analysis","volume":"134","author":"Stein","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.04.016_bib0020","doi-asserted-by":"crossref","first-page":"e248","DOI":"10.1016\/j.clml.2020.12.002","article-title":"Direct medical costs associated with treatment nonpersistence in patients with higher-risk myelodysplastic syndromes receiving hypomethylating agents: a large retrospective cohort analysis","volume":"21","author":"Joshi","year":"2021","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2022.04.016_bib0021","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1080\/10428194.2019.1663423","article-title":"Association of provider experience and clinical outcomes in patients with myelodysplastic syndromes receiving hypomethylating agents","volume":"61","author":"Zeidan","year":"2020","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2022.04.016_bib0022","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1002\/cncr.28631","article-title":"Disparity in perceptions of disease characteristics, treatment effectiveness, and factors influencing treatment adherence between physicians and patients with myelodysplastic syndromes","volume":"120","author":"Steensma","year":"2014","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2022.04.016_bib0023","doi-asserted-by":"crossref","first-page":"60","DOI":"10.6004\/jnccn.2017.0007","article-title":"Myelodysplastic Syndromes, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology","volume":"15","author":"Greenberg","year":"2017","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.clml.2022.04.016_bib0024","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1111\/bjh.14305","article-title":"Comparative clinical effectiveness of azacitidine versus decitabine in older patients with myelodysplastic syndromes","volume":"175","author":"Zeidan","year":"2016","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2022.04.016_bib0025","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1182\/blood-2017-10-811729","article-title":"Long-term survival of older patients with MDS treated with HMA therapy without subsequent stem cell transplantation","volume":"131","author":"Zeidan","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.04.016_bib0026","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1080\/10428194.2019.1703970","article-title":"Hypomethylating agent (HMA) therapy use and survival in older adults with Refractory Anemia with Excess Blasts (RAEB) in the United States (USA): a large propensity score-matched population-based study","volume":"61","author":"Davidoff","year":"2020","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2022.04.016_bib0027","unstructured":"National Cancer Institute. Surveillance, Epidemiology, and End Results (SEER)-Medicare: Brief Description of the SEER-Medicare Database. 2019. Available at: https:\/\/healthcaredelivery.cancer.gov\/seermedicare\/overview. Accessed 15 June 2021."},{"key":"10.1016\/j.clml.2022.04.016_bib0028","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/0895-4356(92)90133-8","article-title":"Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases","volume":"45","author":"Deyo","year":"1992","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.clml.2022.04.016_bib0029","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/s41669-018-0100-5","article-title":"Economic burden of patients treated for higher-risk myelodysplastic syndromes (HR-MDS) in routine clinical care in the United States","volume":"3","author":"Bell","year":"2019","journal-title":"Pharmacoecon Open"},{"key":"10.1016\/j.clml.2022.04.016_bib0030","first-page":"303","article-title":"Obstacles to adherence to azacitidine administration schedule in outpatient myelodysplastic syndrome and related disorders","volume":"23","author":"Tendas","year":"2015","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.clml.2022.04.016_bib0031","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1080\/16078454.2021.1889161","article-title":"Persistence to hypomethylating agents and clinical and economic outcomes among patients with myelodysplastic syndromes","volume":"26","author":"Cheng","year":"2021","journal-title":"Hematology"},{"key":"10.1016\/j.clml.2022.04.016_bib0032","article-title":"Injectable hypomethylating agents for management of myelodysplastic syndromes: patients' perspectives on treatment","author":"Zeidan","year":"2021","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2022.04.016_bib0033","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1182\/bloodadvances.2020002929","article-title":"Cedazuridine\/decitabine: from preclinical to clinical development in myeloid malignancies","volume":"5","author":"Patel","year":"2021","journal-title":"Blood Adv"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265022001331?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265022001331?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:41:09Z","timestamp":1761871269000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265022001331"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":33,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["S2152265022001331"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2022.04.016","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of Hypomethylating Agent Use on Hospital and Emergency Room Visits, and Predictors of Early Discontinuation in Patients With Higher-Risk Myelodysplastic Syndromes","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2022.04.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}